Treatment of renal failure and blood pressure.
Some of the more important advances in slowing progression of renal disease in the past few years include the following: the identification of specific racial groups, such as African-Americans and Mexican-Americans, who are at higher risk for renal disease progression than the general population; the observation that African-Americans may require lower levels of blood pressure reductions (i.e. < 125/75 mmHg) than the general population in order to achieve a similar degree of protection against renal disease progression; the understanding that angiotensin-converting enzyme inhibitors in the early stages of diabetic renal disease and nondihydropyridine calcium-channel blockers in those with established renal insufficiency from diabetes slow renal disease progression and reduce proteinuria; and lastly, aggressive blood pressure reduction in dialysis patients is associated with a reduction in cardiovascular events.
Silverman
M
M
Rush University Hypertension Center, Rush-Presbyterian-St Luke's Medical Center, Chicago, IL 60612, USA.
Bakris
G L
GL
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D015415:Biomarkers; D001794:Blood Pressure / Q000187:drug effects*; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000517:prevention & control; D003928:Diabetic Nephropathies / Q000188:drug therapy / Q000503:physiopathology; D004232:Diuretics / Q000627:therapeutic use; D006801:Humans; D006977:Hypertension, Renal / Q000188:drug therapy / Q000503:physiopathology; D051437:Renal Insufficiency / Q000188:drug therapy* / Q000503:physiopathology*
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D015415:Biomarkers; D002121:Calcium Channel Blockers; D004232:Diuretics